Drug Safety

, Volume 29, Issue 10, pp 953–953 | Cite as

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

  • A. Loraschi
  • E. Martignoni
  • M. Cosentino
  • R. Zangaglia
  • A. Citterio
  • C. Pacchetti
  • G. Nappi
  • S. Lecchini
Abstracts
  • 13 Downloads

Keywords

Haloperidol Dystonia Tardive Dyskinesia Thioridazine Psychiatric Inpatient 

References

  1. 1.
    Caligiuri MR, Jeste DV, Lacro JP. Antipsychotics-Induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17(5): 363–84PubMedCrossRefGoogle Scholar
  2. 2.
    Grohmann R, Koch R, Schmidt LG. Extrapyramidal symptoms in neuroleptic recipients. Agent Action Suppl. 1990; 29: 71–82CrossRefGoogle Scholar
  3. 3.
    Matsui-Sakata A, Ohtani H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 2005 Jun; 20(3): 187–99PubMedCrossRefGoogle Scholar
  4. 4.
    Marsalek M. Tardive drug-induced extrapyramdal syndromes. Pharmacopsychiatry 2000 Sep; 33Suppl. 1: 14–33PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • A. Loraschi
    • 1
  • E. Martignoni
    • 2
    • 3
  • M. Cosentino
    • 1
  • R. Zangaglia
    • 3
  • A. Citterio
    • 3
  • C. Pacchetti
    • 3
  • G. Nappi
    • 4
  • S. Lecchini
    • 1
  1. 1.Department of Clinical Medicine, Section of Experimental and Clinical PharmacologyUniversity of InsubriaVareseItaly
  2. 2.Department of Medical ScienceUniversity of Piemonte Orientale “Amedeo Avogadro”Novara Italy and Department of Neurorehabilitation & Movement Disorders, “Salvatore Maugeri” Foundation, Scientific Institute of Veruno, NOItaly
  3. 3.I.R.C.C.S. Neurological Institute C. MondinoPaviaItaly
  4. 4.Department of Neurology and OtorhinolaryngologyUniversity “La Sapienza”RomeItaly

Personalised recommendations